Why I'm telling friends to avoid gold stocks

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

Sean Power Biography and Net Worth

CFO of TG Therapeutics

Sean A. Power, CPA, has served as the Company’s Chief Financial Officer since December 2011. Mr. Power joined the Company from Keryx Biopharmaceuticals, Inc. (KERX), where he served as Corporate Controller from 2006 to 2011. During his tenure there, Mr. Power was involved in all capital raising and licensing transactions. He was also responsible for leading Keryx’s compliance with Securities and Exchange Commission rules and regulations. Prior to joining Keryx, he was with KPMG, LLP, independent certified public accountants, where he served as a senior associate. Mr. Power received a BBA in accounting from Siena College and is a member of the American Institute of Certified Public Accountants.

What is Sean A. Power's net worth?: The estimated net worth of Sean A. Power is at least $19.54 million as of January 3rd, 2024. Mr. Power owns 606,969 shares of TG Therapeutics stock worth more than $19,544,402 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Power may own. Additionally, Mr. Power receives a salary of $670,580.00 as CFO at TG Therapeutics. Learn More about Sean A. Power's net worth.
How old is Sean A. Power?: Mr. Power is currently 42 years old. There are 1 older executives and no younger executives at TG Therapeutics. The oldest executive at TG Therapeutics is Mr. Michael S. Weiss Esq., Chairman, CEO & President, who is 58 years old. Learn More on Sean A. Power's age.
What is Sean A. Power's salary?: As the CFO of TG Therapeutics, Inc., Mr. Power earns $670,580.00 per year. The highest earning executive at TG Therapeutics is Mr. Michael S. Weiss Esq., Chairman, CEO & President, who commands a salary of $1,970,000.00 per year. Learn More on Sean A. Power's salary.
How do I contact Sean A. Power?: The corporate mailing address for Mr. Power and other TG Therapeutics executives is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. TG Therapeutics can also be reached via phone at (212) 554-4484 and via email at [email protected]. Learn More on Sean A. Power's contact information.
Has Sean A. Power been buying or selling shares of TG Therapeutics?: Sean A. Power has not been actively trading shares of TG Therapeutics during the last ninety days. Most recently, Sean A. Power sold 47,867 shares of the business's stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $16.91, for a transaction totalling $809,430.97. Following the completion of the sale, the chief financial officer now directly owns 606,969 shares of the company's stock, valued at $10,263,845.79. Learn More on Sean A. Power's trading history.
Who are TG Therapeutics' active insiders?: TG Therapeutics' insider roster includes Laurence Charney (Director), Yann Echelard (Director), Sagar Lonial (Director), Sean Power (CFO), and Michael Weiss (CEO). Learn More on TG Therapeutics' active insiders.
Are insiders buying or selling shares of TG Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 92,367 shares worth more than $1,645,995.97. The most recent insider tranaction occured on November, 11th when Director Sagar Lonial sold 5,000 shares worth more than $152,200.00. Insiders at TG Therapeutics own 10.5% of the company. Learn More about insider trades at TG Therapeutics.
Information on this page was last updated on 11/11/2024.

Sean A. Power Insider Trading History at TG Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/3/2024	Sell	47,867	$16.91	$809,430.97	606,969
6/2/2023	Sell	73,647	$26.70	$1,966,374.90	654,836
1/4/2022	Sell	75,312	$19.20	$1,445,990.40
7/1/2019	Sell	17,654	$8.47	$149,529.38
1/2/2019	Sell	37,275	$4.13	$153,945.75
7/3/2018	Sell	47,191	$13.21	$623,393.11	473,267
1/2/2018	Sell	32,006	$8.50	$272,051.00	517,464
6/19/2017	Sell	59,976	$11.09	$665,133.84	477,464
1/4/2017	Sell	8,816	$4.55	$40,112.80
4/18/2016	Sell	10,000	$10.12	$101,200.00	466,682
1/5/2016	Sell	22,790	$11.21	$255,475.90	476,682
7/1/2015	Sell	50,054	$16.46	$823,888.84
4/2/2015	Sell	23,800	$15.50	$368,900.00
1/7/2015	Sell	66,401	$16.40	$1,088,976.40
1/5/2015	Sell	54,057	$16.40	$886,534.80
12/16/2014	Sell	38,041	$16.44	$625,394.04

Sean A. Power Buying and Selling Activity at TG Therapeutics

TG Therapeutics Company Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Today's Range

Now: $32.20

$30.50

$32.63

50 Day Range

MA: $29.62

$22.83

$35.09

2 Week Range

Now: $32.20

$12.84

$36.84

Volume

2,793,497 shs

Average Volume

3,586,359 shs

Market Capitalization

$5.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.25

Why I'm telling friends to avoid gold stocks

From DTI | Ad

And if you’d like to get your hands on this, here you go, the complete breakdown.

Sean Power Biography and Net Worth

What is Sean A. Power's net worth?

How old is Sean A. Power?

What is Sean A. Power's salary?

How do I contact Sean A. Power?

Has Sean A. Power been buying or selling shares of TG Therapeutics?

Who are TG Therapeutics' active insiders?

Are insiders buying or selling shares of TG Therapeutics?